Provided by Tiger Trade Technology Pte. Ltd.

Viridian Therapeutics, Inc.

24.02
-0.2700-1.11%
Post-market: 23.76-0.2600-1.08%18:34 EDT
Volume:1.13M
Turnover:27.27M
Market Cap:2.72B
PE:-6.95
High:24.39
Open:24.35
Low:24.00
Close:24.29
52wk High:34.29
52wk Low:13.18
Shares:113.29M
Float Shares:108.00M
Volume Ratio:0.73
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4579
EPS(LYR):-3.3245
ROE:-65.74%
ROA:-30.16%
PB:4.82
PE(LYR):-7.23

Loading ...

Viridian Therapeutics Chief Legal Officer Jennifer Tousignant Disposes of Common Shares Worth $348,194

Reuters
·
Aug 21

Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT) and Viridian Therapeutics (VRDN)

TIPRANKS
·
Aug 20

Viridian Therapeutics (VRDN) Gets a Buy from Truist Financial

TIPRANKS
·
Aug 13

Is Viridian Therapeutics' (VRDN) Widening Losses Despite Higher Revenue Reframing Its Risk Reward Profile?

Simply Wall St.
·
Aug 10

Viridian Therapeutics (VRDN) Receives a Buy from Evercore ISI

TIPRANKS
·
Aug 10

Viridian Therapeutics (VRDN) Receives a Buy from LifeSci Capital

TIPRANKS
·
Aug 07

Viridian Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Viridian Therapeutics Q2 Net Loss Widens as Lumvoa Launch Lifts Costs

Reuters
·
Aug 06

Viridian Net Loss Widens to $127.12 Million in Q2 FY26; SG&A Expenses Climb to $54.98 Million

Reuters
·
Aug 06

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

THOMSON REUTERS
·
Aug 06

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Viridian Therapeutics (VRDN)

TIPRANKS
·
Aug 05

How Positive Elegrobart REVEAL-1 Phase III Data Could Impact Viridian Therapeutics (VRDN) Investors

Simply Wall St.
·
Jul 30

Wells Fargo Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN)

TIPRANKS
·
Jul 20

Wedbush Sticks to Its Buy Rating for Viridian Therapeutics (VRDN)

TIPRANKS
·
Jul 13

Viridian Therapeutics (VRDN) Could Be 87% Below Fair Value After FDA Approval

Simply Wall St.
·
Jul 11

The Bull Case For Viridian Therapeutics (VRDN) Could Change Following FDA Approval Of Lumvoa For Thyroid Eye Disease

Simply Wall St.
·
Jul 06

Viridian Therapeutics (VRDN) Gets a Buy from RBC Capital

TIPRANKS
·
Jun 30

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Amid Hopes for Renewed US-Iran Diplomacy

MT Newswires Live
·
Jun 29

Viridian Therapeutics Exec Says the Wholesale Acquisition Cost for Five Infusions of Lumvoa is About $450,000 for a Typical 75‑kg Patient

THOMSON REUTERS
·
Jun 29

Viridian Therapeutics Exec Says Five Infusions of Its Thyroid Eye Disease Drug Lumvoa are Priced Roughly in Line with Eight Infusions of Amgen’s Tepezza - Conf Call

THOMSON REUTERS
·
Jun 29